8.91
+0.06(+0.68%)
Currency In USD
Address
500 Arsenal Street
Watertown, MA 02472
United States of America
Phone
617 607 0800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
March 21, 2013
| Name | Title | Pay | Year Born |
| Dr. Jay R. Luly Ph.D. | President, Chief Executive Officer & Director | 1.23M | 1956 |
| Ms. Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer | 496,852 | 1978 |
| Mr. Matthew P. Kowalsky J.D. | Chief Legal Officer & Corporate Secretary | 575,652 | 1973 |
| Mr. Brendan Luu | Chief Business Officer | 622,856 | 1975 |
| Mr. Paul J. Mellett Jr. | Chief Financial & Administrative Officer | 671,700 | 1955 |
| Mr. Nathaniel S. Gardiner J.D. | Consultant | 672,675 | 1954 |
| Dr. Yat Sun Or Ph.D. | Chief Scientific Officer | 740,108 | 1952 |
| Dr. Scott T. Rottinghaus M.D. | Chief Medical Office | 776,138 | 1974 |
| Ms. Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | 0 | N/A |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.